Dr. Tirrell T. Johnson, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 277
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of Florida College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME88326 -
Hematology & Oncology Physician
FL license ME88326 · RI license LF24447 -
Internal Medicine Physician
FL license ME88326
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Orlando Health Orlando, FL
- Orlando Health South Lake Hospital Clermont, FL
- Orlando Health-Health Central Hospital Ocoee, FL
- Orlando Health Melbourne Hospital Melbourne, FL
- Orlando Health St Cloud Hospital Saint Cloud, FL
Medical groups
- Orlando Health Medical Group Inc (2,287 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 277
- Services billed
- 765
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 511 | 191 |
| New patient office or other outpatient visit, 60-74 minutes | 38 | 38 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 30 | 30 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 27 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 24 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 20 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Orlando, FL | 224 |
| Ondansetron Hcl Other prescribers in Orlando, FL | 140 |
| Levothyroxine Sodium Other prescribers in Orlando, FL | 127 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Orlando, FL | 92 |
| Tagrisso (osimertinib mesylate) | 91 |
| Prednisone Other prescribers in Orlando, FL | 83 |
| Dexamethasone Other prescribers in Orlando, FL | 77 |
| Olanzapine Other prescribers in Orlando, FL | 48 |
| Pregabalin Other prescribers in Orlando, FL | 44 |
| Oxycodone Hcl Other prescribers in Orlando, FL | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $304 in total to this clinician.
| Janssen Biotech, Inc. | $157 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $147 |
| Food and Beverage | $304 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 23 industry-funded studies in 2025, from 13 companies. The companies reported $1,665,234 in research payments for these studies, mostly to the institutions running them.
- DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stag…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors
ModernaTX, Inc. - Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc. · Recruiting · NCT05533697 - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05352672 - An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
ModernaTX, Inc. · Active, not recruiting · NCT03897881 - Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors
Boehringer Ingelheim Pharmaceuticals, Inc. - A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals, Inc. · Terminated · NCT04916002 - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM)
Immunocore Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.